Note: As FDA indexes SPL, only VA MED-RT and NDF-RT Classifications that the FDA considers scientifically valid and clinically meaningful are used. Therefore, the drug classes that are available for a DailyMed query represent a subset of all VA MED-RT and NDF-RT classifications.
To find drugs that belong to a specific drug class, type in the drug class in the search box or select from the list of drug classes.
- Decarboxylase Inhibitor [EPC]
- Decarboxylase Inhibitors [MoA]
- Decorporation Agent [EPC]
- Decreased Autonomic Ganglionic Activity [PE]
- Decreased Blood Pressure [PE]
- Decreased B Lymphocyte Activation [PE]
- Decreased Cell Membrane Integrity [PE]
- Decreased Cell Wall Integrity [PE]
- Decreased Cell Wall Synthesis & Repair [PE]
- Decreased Central Nervous System Disorganized Electrical Activity [PE]
- Decreased Central Nervous System Organized Electrical Activity [PE]
- Decreased Cholesterol Absorption [PE]
- Decreased Coagulation Factor Activity [PE]
- Decreased Copper Ion Absorption [PE]
- Decreased Cytokine Activity [PE]
- Decreased DNA Integrity [PE]
- Decreased DNA Replication [PE]
- Decreased Embryonic Implantation [PE]
- Decreased Fibrinolysis [PE]
- Decreased GI Motility [PE]
- Decreased GI Smooth Muscle Tone [PE]
- Decreased Glycolysis [PE]
- Decreased GnRH Secretion [PE]
- Decreased Histamine Release [PE]
- Decreased IgE Activity [PE]
- Decreased Immunologic Activity [PE]
- Decreased Immunologically Active Molecule Activity [PE]
- Decreased Leukotriene Production [PE]
- Decreased Mitosis [PE]
- Decreased Parasympathetic Acetylcholine Activity [PE]
- Decreased Platelet Aggregation [PE]
- Decreased Platelet Production [PE]
- Decreased Prostaglandin Production [PE]
- Decreased Protein Synthesis [PE]
- Decreased Renal K+ Excretion [PE]
- Decreased Respiratory Secretion Viscosity [PE]
- Decreased RNA Integrity [PE]
- Decreased RNA Replication [PE]
- Decreased Sebaceous Gland Activity [PE]
- Decreased Sperm Motility [PE]
- Decreased Striated Muscle Contraction [PE]
- Decreased Striated Muscle Tone [PE]
- Decreased Sympathetic Activity [PE]
- Decreased Tracheobronchial Stretch Receptor Activity [PE]
- Decreased Vascular Permeability [PE]
- Demulcent Activity [MoA]
- Demulcent [EPC]
- Depigmenting Activity [PE]
- Depolarizing Neuromuscular Blocker [EPC]
- Diagnostic Dye [EPC]
- Diarylquinoline Antimycobacterial [EPC]
- Dietary Cholesterol Absorption Inhibitor [EPC]
- Digestive/GI System Activity Alteration [PE]
- Dihydrofolate Reductase Inhibitor Antibacterial [EPC]
- Dihydrofolate Reductase Inhibitor Antimalarial [EPC]
- Dihydrofolate Reductase Inhibitors [MoA]
- Dihydroorotate Dehydrogenase Inhibitors [MoA]
- Dihydropyridine Calcium Channel Blocker [EPC]
- Dipeptidase Inhibitors [MoA]
- Dipeptidyl Peptidase 4 Inhibitor [EPC]
- Dipeptidyl Peptidase 4 Inhibitors [MoA]
- Direct Thrombin Inhibitor [EPC]
- DNA Polymerase Inhibitors [MoA]
- DNA Terminase Complex Inhibitors [MoA]
- DOPA Decarboxylase Inhibitors [MoA]
- Dopamine-2 Receptor Antagonist [EPC]
- Dopamine Agonists [MoA]
- Dopamine D2 Antagonists [MoA]
- Dopaminergic Agonist [EPC]
- Dopamine Uptake Inhibitors [MoA]
- Dyes [MoA]
- Echinocandin Antifungal [EPC]
- Emesis Suppression [PE]
- Endogenous Antigen Neutralization [MoA]
- Endoglycosidase [EPC]
- Endothelin Receptor Antagonist [EPC]
- Endothelin Receptor Antagonists [MoA]
- Epidermal Growth Factor Receptor Antagonist [EPC]
- Epoxide Hydrolase Inhibitors [MoA]
- Ergotamine Derivative [EPC]
- Ergot Derivative [EPC]
- Ergot-derived Dopamine Receptor Agonist [EPC]
- Erythropoiesis-stimulating Agent [EPC]
- Ester Local Anesthetic [EPC]
- Estrogen Agonist/Antagonist [EPC]
- Estrogen [EPC]
- Estrogen Receptor Agonists [MoA]
- Estrogen Receptor Antagonist [EPC]
- Estrogen Receptor Antagonists [MoA]
- Factor VIII Activator [EPC]
- Factor Xa Inhibitor [EPC]
- Factor Xa Inhibitors [MoA]
- Farnesoid X Receptor Agonist [EPC]
- Farnesoid X Receptor Agonists [MoA]
- Fluoroquinolone Antibacterial [EPC]
- Folate Analog [EPC]
- Folate Analog Metabolic Inhibitor [EPC]
- Folic Acid Metabolism Inhibitors [MoA]
- Free Radical Scavenging Activity [MoA]
- Full Opioid Agonists [MoA]
- Fungal Proteins [Chemical/Ingredient]
- Fusion Protein Inhibitors [MoA]
- GABA A Agonists [MoA]
- GABA B Agonists [MoA]
- Gadolinium-based Contrast Agent [EPC]
- gamma-Aminobutyric Acid A Receptor Agonist [EPC]
- gamma-Aminobutyric Acid-ergic Agonist [EPC]
- Gastrointestinal Motility Inhibitor [EPC]
- General Anesthesia [PE]
- General Anesthetic [EPC]
- Genitourinary Arterial Vasodilation [PE]
- GI Motility Alteration [PE]
- Glinide [EPC]
- GLP-1 Receptor Agonist [EPC]
- GLP-2 Analog [EPC]
- Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
- Glucagon-Like Peptide 2 [Chemical/Ingredient]
- Glucagon-like Peptide-2 (GLP-2) Agonists [MoA]
- Glucosylceramide Synthase Inhibitor [EPC]
- Glucosylceramide Synthase Inhibitors [MoA]
- Glycolipid Disialoganglioside-directed Antibody [EPC]
- Glycolipid Disialoganglioside-directed Antibody Interactions [MoA]
- Glycopeptide Antibacterial [EPC]
- Glycosaminoglycan [EPC]
- Gonadotropin [EPC]
- Gonadotropin Releasing Hormone Antagonist [EPC]
- Gonadotropin Releasing Hormone Receptor Agonist [EPC]
- Gonadotropin Releasing Hormone Receptor Agonists [MoA]
- Gonadotropin Releasing Hormone Receptor Antagonists [MoA]
- Growth Hormone Receptor Antagonist [EPC]
- Growth Hormone Receptor Antagonists [MoA]
- Growth Hormone Releasing Factor Analog [EPC]
- Growth Hormone Secretagogue Receptor Agonist [EPC]
- Growth Hormone Secretagogue Receptor Agonists [MoA]
- Guanylate Cyclase Activators [MoA]
- Guanylate Cyclase-C Agonist [EPC]
- Guanylate Cyclase Stimulators [MoA]